Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance
Cristina Cristofoletti, Antonella Bresin, Mario Picozza, et al.
Leukemia (2018) Vol. 33, Iss. 5, pp. 1231-1242
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Multimodal single-cell analysis of cutaneous T-cell lymphoma reveals distinct subclonal tissue-dependent signatures
Alberto Herrera, Anthony Cheng, Eleni P. Mimitou, et al.
Blood (2021) Vol. 138, Iss. 16, pp. 1456-1464
Open Access | Times Cited: 60
Mapping the function of MicroRNAs as a critical regulator of tumor-immune cell communication in breast cancer and potential treatment strategies
Aimi Syamima Abdul Manap, Aini Athirah Wisham, Fei Wen Wong, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 9
Molecular pathogenesis of Cutaneous T cell Lymphoma: Role of chemokines, cytokines, and dysregulated signaling pathways
Kalyani Patil, Shilpa Kuttikrishnan, Abdul Quaiyoom Khan, et al.
Seminars in Cancer Biology (2021) Vol. 86, pp. 382-399
Open Access | Times Cited: 42
Action Mechanism of Metformin and Its Application in Hematological Malignancy Treatments: A Review
Yi Zhang, Fang Zhou, Jiaheng Guan, et al.
Biomolecules (2023) Vol. 13, Iss. 2, pp. 250-250
Open Access | Times Cited: 19
Blood-brain barrier disruption and inflammation reaction in mice after chronic exposure to Microcystin-LR
Jing Wang, Changliang Zhang, Jinling Zhu, et al.
The Science of The Total Environment (2019) Vol. 689, pp. 662-678
Closed Access | Times Cited: 51
Extracorporeal Photopheresis: A Case of Immunotherapy Ahead of Its Time
Pablo Vieyra-Garcia, Peter Wolf
Transfusion Medicine and Hemotherapy (2020) Vol. 47, Iss. 3, pp. 226-235
Open Access | Times Cited: 42
Programmed cell death factor 4 (PDCD4), a novel therapy target for metabolic diseases besides cancer
Kaikai Lu, Qian Chen, Mengda Li, et al.
Free Radical Biology and Medicine (2020) Vol. 159, pp. 150-163
Closed Access | Times Cited: 41
MiR-340-5p alleviates oxygen-glucose deprivation/reoxygenation-induced neuronal injury via PI3K/Akt activation by targeting PDCD4
Yake Zheng, Peng Zhao, Yajun Lian, et al.
Neurochemistry International (2019) Vol. 134, pp. 104650-104650
Closed Access | Times Cited: 42
MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas
Maria Gluud, Andreas Willerslev-Olsen, Lise Mette Rahbek Gjerdrum, et al.
Cancers (2020) Vol. 12, Iss. 5, pp. 1229-1229
Open Access | Times Cited: 37
Spatially Guided and Single Cell Tools to Map the Microenvironment in Cutaneous T-Cell Lymphoma
Eirini Kalliara, Emma Belfrage, Urban Gullberg, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2362-2362
Open Access | Times Cited: 11
Bioinformatics Analysis Finds Immune Gene Markers Related to the Prognosis of Bladder Cancer
Xingyu Chen, Yi Jin, Lian Gong, et al.
Frontiers in Genetics (2020) Vol. 11
Open Access | Times Cited: 28
Advances in Novel Systemic Therapies for the Management of Cutaneous T Cell Lymphoma (CTCL)
Katherine Case, Pamela B. Allen
Current Hematologic Malignancy Reports (2025) Vol. 20, Iss. 1
Closed Access
Linifanib alone and in combination with metronomic chemotherapy is active on cutaneous T-cell lymphoma cells by targeting the AKT/mTOR signaling pathway
Marta Banchi, Maria Christina Cox, Arianna Bandini, et al.
Investigational New Drugs (2025)
Closed Access
Preclinical Evidence for Targeting PI3K/mTOR Signaling with Dual-Inhibitors as a Therapeutic Strategy against Cutaneous T-Cell Lymphoma
Antonella Bresin, Cristina Cristofoletti, Elisabetta Caprini, et al.
Journal of Investigative Dermatology (2019) Vol. 140, Iss. 5, pp. 1045-1053.e6
Open Access | Times Cited: 27
Ruxolitinib with resminostat exert synergistic antitumor effects in Cutaneous T-cell Lymphoma
Fani Karagianni, Christina Piperi, Vassiliki Mpakou, et al.
PLoS ONE (2021) Vol. 16, Iss. 3, pp. e0248298-e0248298
Open Access | Times Cited: 21
CCR7 in Blood Cancers – Review of Its Pathophysiological Roles and the Potential as a Therapeutic Target
Carlos Cuesta‐Mateos, Fernando Terrón, Marco Herling
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 15
Cutaneous Lymphocyte Antigen Is a Potential Therapeutic Target in Cutaneous T-Cell Lymphoma
Sara Peru, Martina Prochazkova‐Carlotti, Floriane Cherrier, et al.
Journal of Investigative Dermatology (2022) Vol. 142, Iss. 12, pp. 3243-3252.e10
Closed Access | Times Cited: 9
CD39/CD73 dysregulation and adenosine metabolism contribute to T-cell immunosuppression in patients with Sézary syndrome
Yuliya Yakymiv, Sara Marchisio, Erika Ortolan, et al.
Blood (2022) Vol. 141, Iss. 1, pp. 111-116
Open Access | Times Cited: 9
ATF5 promotes malignant T cell survival through the PI3K/AKT/mTOR pathway in cutaneous T cell lymphoma
Mengzhou Cao, Pan Lai, Xiangjun Liu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Gene Expression Comparison between Sézary Syndrome and Lymphocytic-Variant Hypereosinophilic Syndrome Refines Biomarkers for Sézary Syndrome
A. Moerman, Syed Jafar Mehdi, Henry K. Wong
Cells (2020) Vol. 9, Iss. 9, pp. 1992-1992
Open Access | Times Cited: 10
Novel therapeutic approaches for cutaneous T cell lymphomas
Antreas Pavlidis, Christina Piperi, Evangelia Papadavid
Expert Review of Clinical Immunology (2021) Vol. 17, Iss. 6, pp. 629-641
Closed Access | Times Cited: 9
<p>Ki67 and CD31 Differential Expression in Cutaneous T-Cell Lymphoma and Its Mimickers: Association with Clinicopathological Criteria and Disease Advancement</p>
Marwa Zohdy, Amal Abd El hafez, Mona Younis Youssef Abd Allah, et al.
Clinical Cosmetic and Investigational Dermatology (2020) Vol. Volume 13, pp. 431-442
Open Access | Times Cited: 9
Genetically Driven CD39 Expression Affects Sezary Cell Viability and IL-2 Production and Detects Two Patient Subsets with Distinct Prognosis
Mario Picozza, Cristina Cristofoletti, Antonella Bresin, et al.
Journal of Investigative Dermatology (2022) Vol. 142, Iss. 11, pp. 3009-3019.e9
Open Access | Times Cited: 6
Vandetanib drives growth arrest and promotes sensitivity to imatinib in chronic myeloid leukemia by targeting ephrin type‐B receptor 4
Weina Ma, Man Zhu, Bo Wang, et al.
Molecular Oncology (2022) Vol. 16, Iss. 14, pp. 2747-2765
Open Access | Times Cited: 5
Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab
Maria Grazia Narducci, Anna Tosi, Alessandra Frezzolini, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top